View in EDS

Purinergic signaling pathway in severe COVID-19.

Saved in:
Bibliographic Details
Title: Purinergic signaling pathway in severe COVID-19.
Authors: Arruvito L; Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina. UBA-CONICET, Paraguay 2155, C1121ABG CABA, Argentina. Electronic address: arruvitol@gmail.com., Sananez I; Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina. UBA-CONICET, Paraguay 2155, C1121ABG CABA, Argentina., Seery V; Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina. UBA-CONICET, Paraguay 2155, C1121ABG CABA, Argentina., Russo C; Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina. UBA-CONICET, Paraguay 2155, C1121ABG CABA, Argentina., Geffner J; Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina. UBA-CONICET, Paraguay 2155, C1121ABG CABA, Argentina.
Source: Current opinion in pharmacology [Curr Opin Pharmacol] 2023 Jun; Vol. 70, pp. 102379. Date of Electronic Publication: 2023 Mar 23.
Publication Type: Journal Article; Review; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 100966133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-4973 (Electronic) Linking ISSN: 14714892 NLM ISO Abbreviation: Curr Opin Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1471-4973
DOI:10.1016/j.coph.2023.102379